Tenderwize
Retour à la recherche

Conclusion of non-exclusive drug discount agreement per §130a(8) SGB V via Open-House model for active substance lanthanum carbonate, chewable tablets

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2028 · 703 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lanthan(III)carbonat in der Darreichungsform Kautabletten

25/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

25 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed minimum purchase quantities; volumes depend on prescribing and dispensing patterns. The buyer explicitly...

The buyer reserves the right to terminate the Open-House procedure early if exclusive discount agreements are signed. T...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclusion of non-exclusive drug discount agreements for lanthanum carbonate chewable tablets.
  • No exclusivity; multiple pharmaceutical entrepreneurs can be contracted simultaneously.
Afficher le résumé complet

This is an Open-House model for concluding non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substance lanthanum carbonate in chewable tablet form (ATC V03AE03). The procedure is open to all pharmaceutical entrepreneurs meeting the requirements, with no exclusivity or guaranteed purchase volumes. The agreement runs until 31 July 2028. The notice explicitly states it is not a public procurement under Directive 2014/24/EU but is published for transparency; the 'open procedure' designation is for technical reasons only.

Risques

No guaranteed minimum purchase quantities; volumes depend on prescribing and dispensing patterns. The buyer explicitly...

The buyer reserves the right to terminate the Open-House procedure early if exclusive discount agreements are signed. T...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered drugs.

Eligibility

  • Must submit declaration of no exclusion grounds per §§123, 124 GWB.

Administrative

  • Must submit declaration regarding Russia sanctions per EU Regulation 833/2014.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified as this is an Open-House model without competition.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Conclusion of non-exclusive drug discount agreement per §130a(8) SGB V via Open-House model for active substance lanthanum carbonate, chewable tablets

Single lot covering the Open-House model for lanthanum carbonate chewable tablets. No estimated value, no minimum quantities. The agreement is non-exclusive and available to all qualified pharmaceutical entrepreneurs.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified as this is an Open-House model without competition.

Date limite

Expired Jul 07, 2026

Détails de la procédure

Date de publication
19 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
344198-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30